bluebird bio opens gene and cell therapy manufacturing facility

bluebird bio has opened its state-of-the-art gene and cell therapy manufacturing facility in Durham, North Carolina.

The facility will produce lentiviral vector for the company’s investigational gene and cell therapies – including bb2121 and bb21217 – for the treatment of multiple myeloma and potentially LentiGlobin for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease.

bluebird bio purchased the facility in November 2017. Once completed, the company will have invested more than $80 million building a world class site equipped with multiple manufacturing suites capable of producing lentiviral vector (LVV).

The facility also includes warehouse and quality control testing laboratories. Construction is substantially complete and equipment qualification is underway.

Initially, bluebird bio expects the facility to produce clinical and commercial supply of lentiviral vector, which is a critical component of the company’s gene and cell therapies.

The facility is large enough to accommodate significant future expansion, including the possibility of manufacturing commercial drug product.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

4D pharma merges with SPAC in $37.6m deal

4D pharma, the listed Leeds-headquartered pharmaceutical company, has merged with Longevity, a special purpose acquisition company (SPAC), in a deal worth up to $37.6...

Cyted acquires Pathognomics Ltd to support expansion of digital pathology and diagnostic reporting services

Cyted Ltd, a developer and provider of artificial intelligence technology and digital diagnostic infrastructure to enable earlier detection of disease, has acquired Pathognomics Limited,...

Record quarter for UK biotech as £1bn is raised

UK biotech companies raised more than £1 billion in equity finance between June and August 2020, the highest quarter for investments in the sector...

Moderna regains rights to RSV vaccine from Merck

Moderna has regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, including rights to develop RSV vaccines for adult populations. mRNA-1172,...

Takeda & Arrowhead to co-develop RNAi therapy for AATLD

Takeda and Arrowhead Pharmaceuticals will collaborate to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver...

Related news

CPhI South East Asia confirms new November date

CPhI South East Asia has postponed its rescheduled event to November 4-6, 2020 to provide more time for positive business conditions to return and...

Execs call for track-and-trace schemes in Southeast Asia – report

Thailand and Indonesia have the largest near-term generics export potential as regional executives come out in favour of an ASEAN-wide track and trace scheme. So...

Winners of CPhI Pharma Awards revealed

The winners of the 2019 CPhI Pharma Awards, which aims to celebrate the industry’s top innovators, performers and outstanding achievements, have been announced. The ‘CEO...

Finalists revealed for CPhI Pharma Awards

The finalists for the CPhI Pharma Awards at the forthcoming CPhI Worldwide event have been announced. The shortlist spans thirteen different award categories covering the...